Akebia Therapeutics Inc (FRA:AX9)
€ 1.642 0.149 (9.98%) Market Cap: 359.71 Mil Enterprise Value: 368.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Akebia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 07:50PM GMT
Release Date Price: €2.46 (-5.38%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

All right. Thanks again for tuning into the JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst. Our next presenting company is Akebia Therapeutics. And here to tell us a little bit about the company is CEO, John Butler.

Before I hand it over for the presentation, I just want to remind folks on the webcast that they can submit a question, and I'm happy to ask on your behalf, by just clicking the Ask a Question icon.

With that, John, thanks for sharing some of your time with us this afternoon.

John P. Butler
Akebia Therapeutics, Inc. - CEO, President & Director

Eric, thank you. Thanks so much for the invitation, and thanks to everyone for joining us today. Before I start, I want to remind everyone that I'm going to be making forward-looking statements. So please refer to our SEC filings for more information. And if you're following along with the slides, I'm starting on Slide 3.

So I'm very, very pleased to be able to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot